<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The microRNA encoding genes miR-34a and miR-34b/c represent direct p53 target genes and possess <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressive properties as they mediate <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, cell cycle arrest, and senescence </plain></SENT>
<SENT sid="1" pm="."><plain>We previously reported that the miR-34a gene is subject to epigenetic inactivation by CpG methylation of its promoter region in primary <z:hpo ids='HP_0012125'>prostate cancer</z:hpo> and <z:hpo ids='HP_0002861'>melanomas</z:hpo>, and in 110 different <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell lines of diverse origin </plain></SENT>
<SENT sid="2" pm="."><plain>Here we analyzed the methylation status of miR-34a and miR-34b/c in additional <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> of divergent sites </plain></SENT>
<SENT sid="3" pm="."><plain>We found methylation of miR-34a or miR-34b/c in formalin-fixed, paraffin-embedded (FFPE) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> samples from 178 patients with the following frequencies: <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (74% miR-34a, 99% miR-34b/c; n = 114), <z:hpo ids='HP_0002894'>pancreatic cancer</z:hpo> (64%, 100%; n = 11), mammary <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> (60%, 90%; n = 10), <z:e sem="disease" ids="C1140680" disease_type="Neoplastic Process" abbrv="">ovarian cancer</z:e> (62%, 69%; n = 13), urothelial <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> (71%, 57%; n = 7), and <z:e sem="disease" ids="C0007134" disease_type="Neoplastic Process" abbrv="">renal cell cancer</z:e> (58%, 100%; n = 12) </plain></SENT>
<SENT sid="4" pm="."><plain>Furthermore, soft tissue <z:hpo ids='HP_0100242'>sarcomas</z:hpo> showed methylation of miR-34 gene promoters in FFPE samples (64%, 45%; n = 11), in explanted, cultured cells (53%, 40%; n = 40), and in frozen tissue samples (75%, 75%, n = 8) </plain></SENT>
<SENT sid="5" pm="."><plain>In the <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> samples a statistically significant correlation of miR-34a methylation and the absence of p53 mutation was detected </plain></SENT>
<SENT sid="6" pm="."><plain>With the exception of <z:hpo ids='HP_0100242'>sarcoma</z:hpo> cell lines, the inactivation of miR-34a and miR-34b/c was concomitant in most cases </plain></SENT>
<SENT sid="7" pm="."><plain>These results show that miR-34 inactivation is a common event in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> formation, and suggest that CpG methylation of miR-34a and miR-34-b/c may have diagnostic value </plain></SENT>
<SENT sid="8" pm="."><plain>The mutual exclusiveness of miR-34a methylation and p53 mutation indicates that miR-34a inactivation may substitute for loss of p53 function in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
</text></document>